Eva Ciruelos
Overview
Explore the profile of Eva Ciruelos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
108
Citations
6330
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alva-Bianchi M, Sanchez-Bayona R, Ciruelos E
Med
. 2025 Feb;
6(2):100602.
PMID: 39954665
The phase 3 EMBER-3 trial demonstrated that when compared to standard therapy, imlunestrant improved progression-free survival (PFS) in advanced ER+/HER2- breast cancer with ESR1 mutations. When combined with abemaciclib, it...
2.
Tolosa P, Pascual T, Martinez-Saez O, Hernando C, Servitja S, Fernandez Abad M, et al.
Eur J Cancer
. 2025 Jan;
217:115219.
PMID: 39779447
Introduction: The prognostic value of PAM50 intrinsic subtypes (IS), cell cycle, and immune-related gene expression in HR+ /HER2- advanced breast cancer (BC) treated with CDK4/6 inhibitors (CDK4/6i) and endocrine therapy...
3.
Schettini F, Nucera S, Pascual T, Martinez-Saez O, Sanchez-Bayona R, Conte B, et al.
Cancer Treat Rev
. 2024 Dec;
132:102865.
PMID: 39709655
Introduction: Antibody-drug conjugates (ADCs) trastuzumab-deruxtecan (T-DXd) and sacituzumab-govitecan (SG) provided significant progression-free survival (PFS) and overall survival (OS) improvements over chemotherapy (CT) in pretreated hormone receptor-positive (HR+) and triple-negative (TN)/HER2-low...
4.
Harbeck N, Ciruelos E, Jerusalem G, Muller V, Niikura N, Viale G, et al.
Nat Med
. 2024 Dec;
30(12):3780.
PMID: 39653780
No abstract available.
5.
Rugo H, Lerebours F, Ciruelos E, Drullinsky P, Ruiz-Borrego M, Neven P, et al.
Lancet Oncol
. 2024 Dec;
25(12):e629-e638.
PMID: 39637900
Background: Alpelisib, a PI3Kα-selective inhibitor and degrader, plus fulvestrant showed efficacy in hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer in SOLAR-1; limited data are available in the post-cyclin-dependent kinase 4/6...
6.
Pernas S, Sanfeliu E, Villacampa G, Salvador J, Perello A, Gonzalez X, et al.
NPJ Breast Cancer
. 2024 Nov;
10(1):101.
PMID: 39592624
With the incorporation of cyclin-dependent kinase inhibitors in early breast cancer (BC), a better identification of biomarkers is needed. The PROMETEO II trial aimed to evaluate the antitumor activity of...
7.
Bartsch R, Cameron D, Ciruelos E, Criscitiello C, Curigliano G, Duhoux F, et al.
Cancer Treat Rev
. 2024 Nov;
132:102853.
PMID: 39580869
Human epidermal growth factor receptor 2 (HER2) overexpression and/or ERBB2 gene amplification occurs in approximately 15-20% of breast cancers and is associated with poor prognosis. While the introduction of HER2-targeted...
8.
Madariaga A, Sanchez-Bayona R, Kasherman L, Estrada-Lorenzo J, Manso L, Tolosa P, et al.
Int J Gynecol Cancer
. 2024 Oct;
PMID: 39379328
Objective: This systematic review aims to evaluate the proactive or real-time assessment of patient reported outcomes in studies involving patients with ovarian cancer undergoing systemic therapy. Methods: PubMed, Embase, and...
9.
Neven P, Stahl N, Vidal M, Martin M, Kaufman P, Harbeck N, et al.
Clin Cancer Res
. 2024 Oct;
30(23):5304-5313.
PMID: 39377773
Purpose: Imlunestrant is an oral selective estrogen receptor degrader with favorable safety and preliminary efficacy in patients with advanced breast cancer. Pharmacodynamic (PD) biomarker data can optimize drug dosing; in...
10.
Harbeck N, Ciruelos E, Jerusalem G, Muller V, Niikura N, Viale G, et al.
Nat Med
. 2024 Sep;
30(12):3717-3727.
PMID: 39271844
Trastuzumab deruxtecan (T-DXd) intracranial activity has been observed in small or retrospective patient cohorts with human epidermal growth factor receptor 2-positive (HER2) advanced/metastatic breast cancer (mBC) and stable or active...